Molecule to Market: Inside the outsourcing space

Barbara’s journey into Biopharma

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Barbara Morgan, Global Vice-President of Pharma and Biotechnology at Kerry.

 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Barbara, covering:

• Believing in herself and being brave enough to leave a company that felt like family in a job that she loved
• Why Pharma has proved itself to be indispensable, while the biopharma slowdown is just a blip
• The difference between mentors and sponsors, and why you need a blend of both
• Lessons for mastering M&A assessment and integration for prioritizing impact

 

Barbara Morgan is Global Vice-President, Pharma, and Biotechnology at Kerry. Prior to that she worked at LLS Health (part of Lubrizol) from 2014 until 2021 and was named General Manager in 2018.

 

With a Ph.D. in Organic Chemistry from the University of Pennsylvania (US), Dr Morgan has more than 15 years of experience in the Life Science industry, covering pharmaceutical, nutraceutical, and medical devices.  She has published numerous articles in peer-reviewed journals and holds patents, including one on the treatment of cancer stem cells.

 

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

 

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

The CDMO CEO that doesn’t sugarcoat

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Marcel Velterop, CEO and Member of the Board at Primopus.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Marcel, covering:

• Tips for technical people looking to transition and navigate into a commercial career path
• Why the CDMO business is not for the faint-hearted given the brutal focus on execution and results
• Insights from a lifetime of doing business in India and the key components of a successful tech transfer across multi-national sites
• How oligonucleotides have gone from niche to mainstream, and why an oligos platform presents a major new tool in the healthcare toolbox

Marcel holds a masters degree in chemical engineering from Delft University of Technology and started his career at DSM where he spent 14 years in various roles of growing responsibility. He then joined Dr Reddy’s Laboratories CPS, a CDMO, and subsequently worked for large Indian providers like Sai Life Sciences and Jubilant Biosys. He gained extensive international experience during his 4 years in the US and now over 15 years in Switzerland and aims to work with cultural differences globally and build productive collaborations.

He found purpose in the pharma industry and helping drive innovation as a service provider in the CDMO and CRO industries. During the Covid times, an opportunity presented itself to work for a large India CDMO, who had acquired a GMP API plant just outside Basel, Switzerland. As CEO of Primopus he is building a hybrid business model with complex RSMs and intermediates supplied out of the Swiss site with full backward integration from the large capacity available in India at its parent company.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Wheeler CDMO Avengers...assemble!

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jesse McCool, Co-Founder and CEO at Wheeler Bio.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jesse, covering:

• His journey from the Lonza bench to the boardroom as CEO of Cytovance CEO before becoming a founder
• Building a CDMO from a blank canvas via a pit stop of C19 testing
• What makes Oklahoma City an attractive place to do business with its mixed blend of life science, tech and biomanufacturing expertise
• How Wheeler’s hub and spoke satellite business model and platform is changing the CDMO business model

Jesse McCool is the Co-Founder and CEO of Wheeler Bio, an agile, small-batch biologics drug substance manufacturer focused on addressing unmet needs in the translational space. He has over 20 years of biologics development and manufacturing experience in biotech and CDMO environments. He previously held executive and technical positions at Cytovance Biologics, Lonza, Lallemand/Mascoma, Dartmouth, and Clean Harbors.

He joined Cytovance Biologics in 2013 to build out and lead the process development organization. The company was acquired by Hepalink in 2015 after which he was named Director, Chief Technical Officer and eventually, Chief Executive Officer. Jesse left Hepalink following the successful HK IPO in 2020 ($500MM USD) to join OKC-based venture studio, Echo Investment Capital, as Entrepreneur-In-Residence. He co-founded and launched Wheeler Bio in 2021.

He also serves on the Governor’s Council for Workforce and Economic Development (State Commerce) and works on numerous workforce development initiatives in the biomanufacturing sector. Jesse earned a Ph.D. from the University of Massachusetts at Amherst and completed his postdoctoral work at Dartmouth (Hanover, NH) and Delft University of Technology (The Netherlands). In addition to his industry experience, Jesse is an established public speaker, researcher, and peer-reviewed journal author and contributor.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

The future is bright, the future is CGT

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Lung-I Cheng, Vice President of Cell & Gene Therapy at AmerisourceBergen.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Lung-I, covering:

• His take on the different models of healthcare he has seen globally, and the value they do and don’t deliver to patients
• The access, and infrastructural challenges of CGT products and ways to bring the cost of goods down
• Why CGT is the therapy of the future... but why we must remember it’s not the only modality out there
• What the future looks like for CGT and exploring what happens when we have a treatment that can treat a lot more patients

Lung-I Cheng, Ph.D., is Vice President, Cell and Gene Therapy, leading AmerisourceBergen’s Cell and Gene Therapy (CGT) service line. In his role, he advances AmerisourceBergen’s CGT strategy with a focus on expanding the company’s portfolio of services to better support CGT innovators throughout the commercialization journey.

Before joining AmerisourceBergen, he spent a decade in biopharma, most recently serving as the head of Global Value & Access for Cell Therapies, Pipeline, and Business Development at Takeda.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

The biopharma boss on a mission against mental health disorders

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Shawn Singh, Chief Executive Officer and Director at Vistagen Therapeutics.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Shawn, covering:

• What life is like running a public company and how that is impacted depending upon the season of the capital markets
• The ups, downs and pivots of a biopharmaceutical company that’s led it down a mission of transforming the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders
• How the pandemic has magnified mental health issues and their prevalence among young people, and why finding a radically social transformative treatment is needed
• Why collaboration is key when developing several drug candidates and how partnerships can happen at any stage of the lifecycle
• His views on CROs, CDMOs, what is essential to outsource in the vendor universe... and the most critical asset to a biotech boss

Shawn is an experienced public company Chief Executive Officer and Director. He has over 30 years of experience working with private and public biotechnology, medical device, and pharmaceutical companies, a venture capital firm, and a profitable contract research and development organization (CRO), serving in numerous senior management roles.

He’s an attorney and a member of the California State Bar with a Juris Doctor from the University of Maryland Francis King Carey School of Law.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

From semiconductors to life sciences

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Wayne Woodard, CEO at Argonaut Manufacturing Services.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Wayne, covering:

• How a career in the famously outsourced semiconductor industry benefited his route into the outsourced life science space
• The basic thesis that led to the start-up of Argonaut and the deliberate intention to ‘skate to where the puck will be’
• Wayne’s aim (and achievement) of creating something special that would also help people and pay forward
• Key considerations and benefits of being located on the West Coast of the USA... including wine

With 35 years of management experience in operations, supply chain and general management, Wayne Woodard’s primary focus (in three different industries) has been on building global operations capabilities with particular emphasis on working with external manufacturing services companies.

Before founding Argonaut, Wayne most recently worked at Thermo Fisher/Life Technologies through its Ion Torrent acquisition. He previously worked at Affymetrix, Electroglas and Ridge Technologies. Wayne began his career in manufacturing at Sun Microsystems. Wayne focuses intensely on execution and detail, which is why he also bottles his own wine.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

The CRO scientist turned entrepreneur

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Richard Weaver, Founder and Managing Director at Drug Discovery Solutions.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Richard, covering:

• How his curiosity to learn at AZ led him to realizing he was an entrepreneur
• The opportunistic start-up story and impressive growth journey of XenoGesis up to the eventual, successful sale to Sygnature Discovery in 2020
• Lessons learned and milestone moments of a scientific entrepreneur
• Why biotechs are here to stay... outsourcing is here to stay... but why offshoring is not

Richard is Founder and Managing Director of Drug Discovery Solutions Limited. Previously CEO and founder of XenoGesis, he grew and led the successful sale of the business to Sygnature Discovery in 2020. Prior to that, he spent 14 years at AstraZeneca.

He is an expert of all aspects of R&D including Due Diligence of companies/assets. Specialist in Drug Metabolism & Pharmacokinetics (DMPK) from Hit Identification (HI) to Candidate Drug (CD) nomination and pre-clinical development.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

CDMO poacher turned biotech gamekeeper

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Vishnu Dwadasi, Director of Manufacturing at Ashvattha Therapeutics Inc.

 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Vishnu, covering:

• Lessons learned from 15 years in CDMOs and consulting, before joining a start-up drug development company
• What he’s learned from working with and managing CDMOs all over the world
• Why many CDMOs are behind the eight-ball... fancy marketing meets chaotic operations
• The challenge of scaling up through phases as a drug sponsor, and the evolving needs when it comes to outsourcing
• Major frustrations as a client in a post-covid world and the one area every CDMO needs to invest in moving forward

 

Vishnu Dwadasi is currently a Director of Manufacturing at a biopharmaceutical start-up company, Ashvattha Therapeutics, leading drug programs from pre-clinical to commercialization.

Vishnu brings over a decade of experience in life sciences with a unique background in pharmaceutical operations, consulting, and business development. He has developed extensive experience shepherding complex drug development programs from early clinical development to full-scale commercial manufacturing and distribution. Along with his drug development experience, Vishnu has gained expertise in operations and implementing technology solutions for life sciences companies.

Vishnu earned an MBA from Duke University and a B.S. in Health Sciences from Purdue University.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Q123 M&A roundtable

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with:

• Ross Burn, Chief Executive at CatSci
• James Hales, Senior Director at NorthEdge
• Tom Cowap, Managing Director for Pharma Services at Baird

Your host, Raman Sehgal, discusses pharmaceutical and biotechnology supply chain M&A activity with his guests, covering:

• How the market headwinds, continued consolidation and macro slowdowns are impacting M&A activity in our space... if at all...
• Why PE is still very keen on the pharma and biotech ecosystem and why the size and shape of deals and investments in the market have changed.
• How an investment is enabling Ross’ business to accelerate growth in several directions.
• A look forward to geographic shifts, continued biotech outsourcing, and how there maybe riches in the niches of sub-segments of the pharma services ecosystem.

After completing his PhD in 2007, Ross joined AstraZeneca as a Senior Analytical Chemist in process R&D. Ross’ analytical expertise and entrepreneurial mindset was pivotal to the establishment of CatSci Ltd in 2011. Ross became CEO in 2015 and has since led the company’s pivot from a catalyst screening company to the award-winning innovation partner for medicines development that it is today. As such, Ross was included on the 2021 edition of The Medicine Maker’s annual Power List of inspirational professionals in the pharmaceutical industry. CatSci received PE backing in 2022.

James is a Senior Director at NorthEdge and leads the healthcare origination efforts as part of the wider healthcare sector team. He is fortunate to meet with management teams nationally across a number of sub-sectors to understand their plans and to identify new investment opportunities for NorthEdge via growth and development capital, management buy-outs, equity release and buy-and-build opportunities. Prior to joining NorthEdge, James spent seven years in Corporate Finance at Clearwater International where he was a Director responsible for generating mid-market opportunities and managing the Deal Origination team.

Tom is a Managing Director in Baird’s European Healthcare Investment Banking team. Tom joined Baird from Alantra where he spent nine years building Alantra’s pharma services coverage effort, providing M&A services for financial sponsors and independently owned, founder backed businesses in the space. Prior to Alantra, Tom worked at PricewaterCoopers in their Financial Due Diligence team. He also served in the British Army (Reserve – 7th Battalion, The Rifles and 4th Battalion, The Yorkshire Regiment). Tom is an ACA and had a bachelor’s degree in finance from Durham University.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

 

Meet the future of bioreactors

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Will Patrick, CEO at Culture Biosciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Will, covering:

• How time at Google, MIT and Kendall Square led him to build disruptive tools and hardware for the bioprocessing sector
• Creating a cloud-based, real-time data alternative for companies wanting access to bioreactors... without the need for large-scale investment
• Why biotech and biopharma firms are embracing digitization, virtualization, and simulation... but less so at CDMOs
• Raising funds from VCs that understand the need for technological disruption
• How biotechs, biopharma companies, and CDMOs alike can leverage Culture’s proprietary, integrated, and cloud-based single-use reactor platform
• How enhanced data-driven modeling and simulation can save a lot of time and costs in upstream bioprocess development going forward

Will is an entrepreneurial engineer with a background in mechanical engineering, product design, and bioengineering. He develops hardware products at the interface of biology and digital fabrication. He holds 17 patents and has published 4 peer-reviewed journal articles. He currently runs Culture Biosciences, a company building and operating automated bioreactor infrastructure for the biotech industry.

Will graduated from the MIT Media Lab in 2015 where he was a researcher in the Mediated Matter group. His research focuses on 3D printing fluidic systems and their applications in biotechnology and product design.

Previously, he worked at Google[x] as a Rapid Evaluator where he developed and prototyped new projects for the organization. Will was a founding member of the Google[x] UAV delivery project, Project Wing, was an early team member of Project Loon, and also led the launch communications for Project Glass.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.